Not Yet RecruitingEarly Phase 1ketamine

Ketamine and Lidocaine Infusion in Refractory Chronic Migraine

Sponsored by Assiut University

NCT ID
NCT06935552
Target Enrollment
44 participants
Start Date
2025-06-01
Est. Completion
2026-12

About This Study

Ketamine and lidocaine infusion for refractory chronic migraine: Comparative Study

Conditions Studied

Refractory Chronic Migraine

Interventions

  • Ketamine infusion
  • Lidocaine Intravenous Infusion
  • Dextrose 5% in water

Eligibility

Age:18 Years - 60 Years
View full eligibility criteria
Inclusion Criteria:

* All participants must fulfill the following inclusion criteria

  1. medically stable outpatients with confirmed diagnosis of refractory chronic migraine according to American Headache society
  2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow up.
  3. Men or women older than 18years of age.
  4. clear written informed consent from each participant in the trial.
  5. Adult patients with refractory migraine or refractory chronic migraine defined according to the American headache society

Exclusion Criteria:

1. Pregnancy, active psychosis, liver disease, uncontrolled cardiac disease or cardiac rhythm abnormalities
2. presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study
3. participation in any other type of medical research that may interfere with the interpretation of the study.
4. patients with hemocoagulation disorders, local infection or those who refused to consent

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

AbdElRahman Mohamed Mohamed
CONTACT
+201066586931hmdmhmmdl1692@gmail.com
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source